Table 2.

The prevalence of aAbs to type I IFNs in 622 patients with COVID-19 according to disease severity or age

aAbs detected by ELISA
Severity	No. of patients	IFN-α2	IFN-ω	IFN-α2 and IFN-ω	IFN-α2 or IFN-ω
Mild	105	1 (1.0% [0.2–5.2])	3 (2.9% [1.0–8.1])	0 (0.0%)	4 (3.8% [1.5–9.4])
Moderate	112	1 (0.9% [0.2–4.9])	0 (0.0%)	0 (0.0%)	1 (0.9% [0.2–4.9])
Severe	235	2 (0.9% [0.2–3.1])	2 (0.9% [0.2–3.1])	0 (0.0%)	4 (1.7% [0.7–4.3])
Critical	170	8 (4.7% [2.4–9.0])	6 (3.5% [1.6–7.5])	4 (2.4% [0.9–5.9])	10 (5.9% [3.2–10.5])
Total	627	12	11	4	19
Age (years)	No. of patients	IFN-α2	IFN-ω	IFN-α2 and IFN-ω	IFN-α2 or IFN-ω
0–49	175	1 (0.6% [0.1–3.2])	2 (1.1% [0.3–4.1])	0 (0.0%)	3 (1.7% [0.6–4.9])
50–	447	11 (2.5% [1.4–4.4])	9 (2.0% [1.1–3.8])	4 (0.9% [0.3–2.3])	16 (3.6% [2.2–5.7])
50–59	127	5 (3.9% [1.7–8.9])	4 (3.2% [1.2–7.8])	2 (1.6% [0.4–5.6])	7 (5.5% [2.7–10.9])
60–69	112	1 (0.9% [0.2–4.9])	1 (0.9% [0.2–4.9])	0 (0.0%)	2 (1.8% [0.5–6.3])
70–	208	5 (2.4% [1.0–5.5])	4 (1.9% [0.8–4.8])	2 (1.0% [0.3–3.4])	7 (3.4% [1.6–6.8])